Check the Issues in U.S. Outbound Tech Investment Rule Expansion and China's Objections

How did the U.S. Treasury broaden the scope of regulated technologies?

The U.S. Department of the Treasury unveiled a Notice of Proposed Rulemaking (NPRM) to implement the Comprehensive Outbound Investment National Security Act of 2025 (COINS Act). The statutory initiative aims to prevent American capital and expertise from advancing military and surveillance capabilities in countries of concern.

The proposed framework adds three new technology domains to the existing trio of semiconductors and microelectronics, artificial intelligence, and quantum information technologies: biotechnology, high-performance computing (supercomputing), and hypersonic systems. Within biotechnology, the rules cover brain-computer interfaces (BCI), genetic therapies, and specialized manufacturing equipment.

The regulatory structure operates across two distinct tracks depending on the sensitivity of the technology. High-risk transactions that directly threaten national security face outright prohibitions, while transactions involving other sensitive dual-use technologies require formal advance notification to the Treasury. The geographic scope encompasses designated countries of concern, including China (along with Hong Kong and Macau), Russia, North Korea, Iran, and Cuba.

What official stance did China's Ministry of Commerce announce?

China's Ministry of Commerce released a formal statement on October 24 expressing grave concern and firm opposition. A spokesperson characterized the draft regulations as discriminatory measures that improperly broaden national security concepts to suppress foreign trade and investment.

The ministry emphasized that the unilateral restrictions breach understandings reached between the heads of state of both nations. Chinese officials further stated that restricting normal commercial partnerships disrupts global supply chains and creates unnecessary market volatility.

Beijing asserted that it will closely track future developments and reserves the right to enact corresponding countermeasures. Concurrently, the ministry underscored China's substantial consumer demand and industrial capacity, urging Washington to halt the weaponization of economic and trade policies.

What are the primary differences between current and proposed regulations?

Comparing the existing Executive Order framework with the statutory COINS Act proposal clarifies the scope and impact of the evolving restrictions.

What consequences are emerging for global life sciences and biotech markets?

The formal addition of biotechnology to outbound investment restrictions has introduced substantial complexity for global biopharmaceutical companies. Broadening capital controls from advanced computing and artificial intelligence into medical research and life sciences represents a significant expansion of regulatory oversight.

Multinational pharmaceutical corporations and cross-border research consortia face growing compliance scrutiny over joint research programs and clinical development hubs located in China. Early-stage startups specializing in neural interfaces and cell therapies anticipate tighter capital environments as U.S. venture funds assess regulatory risks before deploying capital.

Nevertheless, the Treasury Department is considering explicit exemptions for standard commercial transactions, including non-equity pharmaceutical distribution and pure licensing agreements. Such carve-outs seek to maintain international medical collaboration for essential therapies while preventing unwanted transfers of dual-use biosecurity technologies.

What upcoming milestones and follow-up actions should be monitored?

The published NPRM is not a finalized regulation with immediate legal force. The Treasury Department has established a 60-day public comment window extending through December 7, 2026, allowing industry stakeholders and legal specialists to submit feedback.

During the public comment period, leading industry associations such as the Biotechnology Innovation Organization (BIO) and Semiconductor Industry Association (SIA) are preparing detailed submissions advocating for narrow definitions and clear safe harbors. Following public feedback and interagency evaluations, the Treasury will publish a final rule and effective date in the first half of 2027.

You can monitor the December 7, 2026 public comment deadline and subsequent final rulemaking releases from the U.S. Treasury. For information verified after October 25, 2026, check upcoming Federal Register notices and formal announcements from China's Ministry of Commerce.